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Abstract
Scintigraphy of the skeletal system is performed mainly with 
the use of 99mTc-MDP. There are other radiopharmaceuticals 
showing affinity to bone lesions: 99mTc-MIBG, 201Tl, 131I (in the 
case of papillary or follicular thyroid cancers), and 99mTc (V) 
DMSA (in the case of medullary cancer). Currently, positron 
emitted radioisotopes are also used in clinical practice. It seems 
that 18F-NaF/PET is a highly sensitive and specific modality for 
detection of metastases and other bone lesions. Certain data 
concerning the role of 18F-FDG, 18F-choline, or 68Ga-DOTATATE 
can be found. The aim of this article is to review the role of 
18F-NaF and 18F-FDG in diagnosis of bone metastases. 
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Introduction
The number of patients suffering from neoplasm in Europe 
amounts to over 3 million people, while mortality reaches 1.7 million 
people a year. Neoplastic metastases to the skeletal system occur 
in 50% of oncologic patients. In 70% of cases they are connected 
with the presence of breast and prostate cancer. The presented 
epidemiologic data indicate the clinical importance of diagnosing 
metastatic foci to the skeletal system. 
Evaluation of disease stage prior to prescribing treatment 
plays a fundamental role in oncologic disease as it allows an op-
timal therapy scheme to be chosen. It involves imaging diag-
nostics of the skeletal system. Due to limitations in diagnostic 
methods, clear evaluation of lesions within the skeletal system 
still remains a clinical issue. 
The presence of metastatic foci depends on two basic phe-
nomena: angiogenesis and neoplastic cells producing adhesion 
factors that allow the cells to develop outside primary tumour site. 
The presence of activated osteoclasts, osteoblasts, inflammatory 
cells, and neoplastic cells is observed in metastatic focus. Multidi-
rectional interactions can be noticed between these components. 
The majority of neoplastic cells show an ability to produce and 
release numerous factors that promote osteoclast multiplication, 
differentiation, and activation.
Radiology tests
Metastatic lesions in the bone in the initial phase infiltrate 
bone marrow, then surround the bone and thus disturb the 
balance enhancing osteolytic or osteoblastic processes. 
Radiologic evaluation distinguishes three types of metastatic 
lesion to bone: lytic, sclerotic, and mixed. Fast-development 
and aggressive metastases usually have a lytic nature, while 
slow-development metastases are typically accompanied by 
osteoblastic processes. The latter observed within the bone 
might also indicate regeneration processes. Lytic lesions mainly 
accompany metastases of the urinary bladder, kidney, and thy-
roid cancer as well as melanoma. Osteoblastic lesions typically 
develop in the case of cancer of: prostate, mammary gland, 
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sometimes lungs, stomach, pancreas, head, and neck and 
rarely large intestine [1]. 
Metastatic foci are visible in computer tomography when bone 
density decreases by 30–75%. In the initial stage of the disease, 
the method is not recommended in the initial diagnostics of skeletal 
system metastases due to limited sensitivity.
Magnetic Resonance Imaging allows for evaluation of neoplas-
tic lesions within bone marrow due to high sensitivity. However, 
the specificity of this method is moderate (differentiation of active 
proliferative lesions with scars, necrosis, angioma, or fracture). 
MRI fails to provide evaluation of bone structures, which is critical 
for diagnosis in a number of cases (calcified structures do not 
emit MRI signal).  
Another limitation to radiology methods (X-rays, CT, MRI) is the 
scope of the tests — they typically involve a particular part of the 
body. Radioisotope techniques allow for a precise evaluation of 
the whole skeleton. Due to the functional character of radioisotope 
techniques the tests are more sensitive: metastatic foci are visible 
in the case of a-few-percent decalcification. Therefore, radioiso-
tope tests are currently considered as the “gold standard” in the 
evaluation of oncologic disease stage. It seems that whole body 
MRI with the use of diffusion sequences will play a similar role. 
Scintigraphic test with the use of 99mTc-MDP
Bone scintigraphy with the use of 99mTc-MDP allows for de-
tection of foci of improper radiopharmaceutical accumulation at 
an early stage of the disease when decalcification amounts only 
to 5–10% compared to healthy bone tissue. Thus, in scintigraphic 
studies the lesions are visible 2–18 months earlier than in radiol-
ogy tests [1]. 
The accumulation mechanism of 99mTc-MDP has not been 
fully understood so far. Neither a relation between osteoblast 
number and the substance accumulation level nor tracer accumu-
lation in collagen have been observed in clinical trials. This sug-
gests that 99mTc-MDP accumulates in bone tissue as a result of 
chemical absorption and incorporation into the hydroxyapatite 
structure. This accumulation depends on the type of the disease 
and micro-environmental conditions such as pH and phosphate 
concentration. The described 99mTc-MDP accumulation mecha-
nisms explain certain method limitations, among others lower 
test sensitivity in diagnostics of metastases with domination of 
osteolytic lesions and lower osteoblast activity or osteolytic me-
tastases with fast bone damage [1]. Lytic lesions are visible in 
scintigraphic studies as “cold” areas that are difficult to interpret. 
The clinical importance of this method is presented in the article 
by M. Bączyk published in this journal issue. 
PET 
The first radiopharmaceutical used for imaging skeletal le-
sions was sodium fluoride (18F-NaF), introduced in the sixties. In 
the seventies phosphonate labelled derivatives were introduced 
into scintigraphy [2]. Their sensitivity, diagnostic effectiveness, 
and cost appeared to be so attractive that studies with the use 
of 18F-NaF became considerably limited. However, currently, due 
to PET-CT development, an increasing interest in this radiophar-
maceutical can be observed [3]. The second frequently used 
radiopharmaceutical in bone metastases diagnostics is 18FDG. In 
many cases the studies that use both tracers are complementary. 
18F-NaF
This radiopharmaceutical was first used by Blau et al. [4] in 
1962. Considerably better PET resolution and 18F-NaF pharma-
cokinetic properties make it a great tracer in evaluation of bone 
metastases [5] and lesions in the course of trauma and metabolic 
diseases. This radiopharmaceutical was registered by the FDA 
as a safe and effective drug in diagnostics of skeletal diseases. 
The 18F dose applied in diagnostic studies is less than 8.4 μg/kg. 
Therefore, no pharmacodynamic effect of the radiopharmaceutical 
is observed. Data on toxicity, genotoxicity, or cancerogenesis are 
not known as the preparation dose used in the study is trace and 
typically administered only once. No studies connected with the 
radiopharmaceutical effect on the foetus have been carried out. 
However, the rules of patient radiology protection should be the 
same as in the case of other radioactive preparations. 
No data on radiopharmaceutical content in breast milk of 
nursing mothers can be found. Thus, breastfeeding ought to 
be stopped. The safety of the 18F-NaF effect on children has not 
been determined. Thus, the study on this group of patients can 
be conducted following a profound analysis of risks and ben-
efits (similarly to other pharmaceuticals from this group, par-
ticularly the intense accumulation of 18F-NaF which takes place 
within epiphyseal cartilage). The dose of absorbed radiation for 
particular organs is between 0.0028 mGy/MBq (for mammary 
glands), 0.028, and 0.019 mGy/MBq (for bone marrow and kid-
neys, respectively). As regards the wall of the urinary bladder, it 
amounts to 0.25 mGy/MBq (FDA, 2000).
No pharmaceutical interactions with other medicines are known. 
The studies on chemical purity indicate that basic chemical sub-
stances present in pharmaceutical solution are silver salts. They 
have trace concentration of maximum 0.3 ug/ml. Also, radiochemical 
purity in reference to radioisotopes of half-life over 2 hours was ex-
amined. Their content is within background limits. No significant risk 
connected with their presence has been observed. 
The pharmacokinetics of 18F-NaF were recently described 
by Modlin et al. [6]. Accumulation level of 18F-NaF in the skeletal 
system depends most of all on blood flow. Almost all fluorides ac-
cumulate in bone tissue as early as during the first passing. Ac-
cumulation within bone marrow is scarce. 
The accumulation mechanism of 18F-NaF involves fast chemi-
sorption on hydroxyapatite crystals. Next, they are exchanged with 
hydroxyl groups, which leads to formation of fluoroapatite. The 
process of fluoride incorporation into bone matrix might last for 
as long as many weeks and depends on osteoblastic and osteo-
lytic process intensity. Fluorides accumulate mainly in the surface 
layer of the bone (within which “remodelling” processes are the 
most intense). Thus, the fluoride accumulation level depends on 
blood flow but also on the surface of the bone structure, which 
is considerably greater in disease foci in the case of both benign 
and malignant disease. It should be emphasized that the surface 
of the bone layer in a sample weighing 1 gram amounts to 300 m2. 
Accumulation of 18F-NaF within metastases is 3–10 times greater 
compared to healthy bone tissue. 
Contrary to 99mTc-MDP, the pharmaceutical does not connect 
with plasma protein and thus is quickly excreted from kidneys to 
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urine. Also, pharmaceutical affinity to cell membranes or other 
cell structures has not been observed.  Radioactivity in red blood 
cells is two times lower than in the plasma and amounts to ap-
proximately 30% of the administered dose. Since fluoride exchange 
between intra- and extracellular space is based on free diffusion, it 
has no significant impact on the quality of the obtained scintigraphy 
images (on the degree of background radiation). Therefore, the 
test might be performed considerably earlier than in the case of 
99mTc-MDP application. Two hours after intravenous administration 
of 18F-FDG to the patient with normal kidney function approximately 
50% of the pharmaceutical accumulates in the skeletal system, 
while over 20% of the dose is excreted with urine [5]. One hour after 
administration blood plasma shows only 10% of total radioactivity. 
Renal clearance for 18F-NaF is similar to the GFR value (70–90% 
of GFR value). The level of pharmaceutical excretion with urine 
depends on diuresis value and urine pH. The dependency on pH 
indicates that the fluoride is reabsorbed in renal tubules (in the 
form of hydrogen fluoride). Increased diuresis reduces radiop-
harmaceutical reabsorption. Therefore, proper hydration of the 
patients before and after 18F-NaF administration is particularly 
important. Thiazides increase 18F excretion and decrease its urine 
concentration (due to diuresis increase). 
The greatest radiopharmaceutical accumulation takes place 
between the 45th and 90th minutes after administration. The test 
is performed every 60 minutes after intravenous administration of 
250–450 MBq (8–12 mCi) of 18F-NaF. Typically, the acquisition/bed 
time amounts to 2–5 minutes [5]. The test should include the whole 
body: from the top of the skull to the feet (in certain centres — to 
1/2 of femoral bones). 
18F-NaF accumulates in all the areas of the skeletal system, par-
ticularly within the spine and pelvis and also in periarticular areas. 
Increased accumulation of the tracer in metastases foci is ob-
served in the case of both osteoblastic and osteolytic lesions (each 
osteolytic lesion is even accompanied by low osteoblastic activity; 
this can be observed in PET but not always in SPECT). Thus, PET 
with the use of 18F-NaF is more sensitive compared to scintigraphy 
with the use of 99mTc-MDP. 
Similarly to 99mTc-MDP, 18F-NaF also accumulates in benign le-
sions, which is a limitation to the method in oncologic diagnostics. 
Increased 18F-NaF accumulation is observed in inflammations, past 
trauma, fibrous dysplasia, Paget’s disease, hyperostosis frontalis, 
and myositis ossificans [5, 6]. Differentiation of these lesions with 
metastatic foci based on tracer uptake (SUV) is impossible, which 
considerably impedes test result interpretation. 
18F-NaF test is not applied in routine diagnostics of bone 
metastases due to limited availability and cost.  Indications for 
18F-NaF test are as follows: high risk of tumour dissemination to 
bone despite normal or unclear 99mTc-MDP scintigraphy picture 
and diagnosis of neoplastic disease with osteolytic bone metas-
tases [7–9]. It is currently assumed that diagnosis of lung, mam-
mary gland, and prostate cancer are basic indications for the test 
with the use of 18F-NaF [7]. 
Schirrmeister et al. [10] compared PET diagnostic effective-
ness following 18F-NaF administration to a scintigraphic test follow-
ing 99mTc-MDP administration in diagnostics of bone metastases of 
various lytic tumours. Additionally, CT, MRI, and scintigraphy were 
performed following administration of 131I. The examined group 
included 44 patients with cancer of prostate, lung, or thyroid. The 
18F-NaF test revealed 96 metastatic lesions in 15 individuals, while 
99mTc-MDP revealed only 46. The 18F-NaF study revealed all the 
lesions observed in the 99mTc-MDP study. The differences between 
the studies referred mainly to metastatic lesions within the spine. 
Scintigraphy with the use of 99mTc-MDP showed the presence of 
40% of metastatic lesions in this area.  PET sensitivity amounted 
to 91.6%, while scintigraphy amounted to 41.7% in diagnosing 
metastatic lesions of both osteolytic and osteoblastic nature. 
Bury et al. [11] compared the sensitivity and specificity of 
PET/CT test with 18F-NaF and scintigraphy after 99mTc-MDP admi-
nistration in 110 patients. The sensitivity of both PET and classic 
scintigraphy amounted to 90%, while specificity was 98% and 
61%, respectively. 
Even-Sapir et al. [1] compared studies with the use of 
99mTc-MDP (WB, SPECT) as well as with the use of 99mTc-MDP 
performed on 44 patients with prostatic cancer and high risk 
of bone metastases. Sensitivity, specificity, positive predictive 
value (PPV), and negative predictive value (NPV) were as follows: 
for WB — 70%, 57%, 64% and 55%, respectively, for SPECT 
— 92%,82%, 86%, and 90%, respectively, for PET — 100%, 62%, 
74%, and 100%, respectively, while in the case of PET/CT all the 
parameters amounted to 100%. 
In 2010 the institutions responsible for recording the clini-
cal effectiveness of medical procedures according to based 
evidence medicine (Medicare, CMS) commenced a program 
evaluating skeletal system scintigraphy with the use of 18F-NaF. 
The study has prospective character and is aimed at answering 
the following question: Does the result of 18F-NaF scintigraphy 
allow the choice of a more suitable treatment or palliative therapy 
which would lead to improvement of life quality or lengthening 
life? According to internet data (February 2011) of the American 
Board of Nuclear Medicine, the National Cancer Institute handed 
the Food and Drug Administration a recommendation of 18F-NaF 
registration as an alternative to 99mTc-MDP pharmaceutical for 
skeletal system studies. The Institute stated that an increase in 
18F-NaF availability would hopefully reduce the cost of the study. 
It should be emphasized that the first 18F-NaF registration by the 
FDA was performed in 1972. In 1975 commercial production of 
18F-NaF was stopped. In 2000 the FDA again issued an opinion 
on the usefulness and safety of this pharmaceutical. 
18F-FDG 
18F-FDG is the most commonly used tracer in diagnostics of 
neoplastic disease with the use of PET technique. Contrary to 
18F-NaF, this radiopharmaceutical is not bone specific. However, 
it should be emphasized that compared to other diagnostic meth-
ods, 18F-FDG has a great property which allows for direct imaging 
of metastatic lesions (the radiopharmaceutical accumulates in neo-
plastic cells, while other methods allow determination of indirect 
signs of the disease). 18F-FDG is transported to cells by transport 
protein present in the Glut cellular membrane. A considerably 
higher Glut 1 protein expression is observed in neoplastic cells. The 
protein transports glucose to the cell without insulin participation. 
The process of phosphorylation takes place in the cell. 
In normal bone marrow low glucose metabolism can be 
typically observed and thus accumulation of 18F-FDG is also low. 
Increased glucose metabolism also occurs in early stage of me-
tastasis, during bone marrow infiltrate before any visible reaction 
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of bone tissue. Therefore, the foci diagnosed following 18F-FDG 
administration might not be visible in CT and scintigraphy. 
The sensitivity of 18F-FDG PET in detecting bone metastas-
es amounts to 62–100% while specificity amounts to 96–100% [1]. 
PET with 18F-FDG allows for diagnosis of skeletal metastases of 
various natures: osteolytic, osteosclerotic, and mixed. However, 
it is more sensitive in detecting osteolytic lesions rather than 
osteosclerotic in coomparison to methods with the use of other 
radiopharmaceuticals. Metser et al. [12] observed increased 
18F-FDG accumulation in 100% of the lesions described as lytic 
in CT and in 88% of the lesions described as sclerotic. Current 
observations indicate that test sensitivity in metastatic foci diag-
nostics is at least comparable to scintigraphy with the use of 
18F-FDG. However, a number of reports suggest that sensitivity of 
18F-FDG-PET is lower than in scintigraphy with the use of 99mTc-MDP 
in mammary gland cancer. Similarly, this radiopharmaceutical 
is less useful in diagnostics of prostatic cancer. However, in 
evaluation of lymphoma metastatic foci this method has a higher 
sensitivity. 
Conclusions
Studies on the skeletal system with the use of PET/CT are used 
in clinical practice more and more often. In particular, the role of 
18F-NaF is emphasized. In recent years, a number of scientific in-
stitutions have commenced regular prospective studies regarding 
the usefulness of this radiopharmaceutical. It is stressed that the 
use of 18F-NaF allows: 
— the earliest identification of skeletal metastatic lesions;
— precise determination of neoplastic disease stage (in reference 
to skeletal system involvement);
— determination of biopsy site, if necessary for final diagnosis;
— monitoring response to the treatment. 
Values of this technique include: 
— two-fold greater tracer accumulation in skeletal system com-
pared with 99mTc-MDP; 
— considerably quicker 18F-NaF excretion from blood (due to 
lack of affinity to blood proteins);
— high value of bone tissue/background coefficient; 
— shorter test duration; 
— easy patient preparation for the test; no limitations to diet of 
physical activity are required;
— possibility of conducting the test regardless of glucose con-
centration in the blood. 
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